Fluidigm Stock Forecast, Price & News

+0.11 (+1.51 %)
(As of 07/30/2021 04:41 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume882,299 shs
Average Volume1.85 million shs
Market Capitalization$555.48 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive FLDM News and Ratings via Email

Sign-up to receive the latest news and ratings for Fluidigm and its competitors with MarketBeat's FREE daily newsletter.

Fluidigm logo

About Fluidigm

Fluidigm Corporation creates, manufactures, and markets technologies and life sciences tools worldwide. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, Hyperion tissue imager, and flow conductor; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow., as well as Maxpar direct immune profiling assays and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 system, Polaris system, C1 IFCs, and Polaris IFC. Fluidigm Corporation sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was founded in 1999 and is headquartered in South San Francisco, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.92 out of 5 stars

Medical Sector

370th out of 2,216 stocks

Analytical Instruments Industry

7th out of 36 stocks

Analyst Opinion: 3.5Community Rank: 3.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Fluidigm (NASDAQ:FLDM) Frequently Asked Questions

Is Fluidigm a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fluidigm in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Fluidigm stock.
View analyst ratings for Fluidigm
or view top-rated stocks.

What stocks does MarketBeat like better than Fluidigm?

Wall Street analysts have given Fluidigm a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Fluidigm wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Fluidigm's next earnings date?

Fluidigm is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Fluidigm

How can I listen to Fluidigm's earnings call?

Fluidigm will be holding an earnings conference call on Thursday, August 5th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Fluidigm's earnings last quarter?

Fluidigm Co. (NASDAQ:FLDM) posted its quarterly earnings results on Thursday, May, 6th. The medical research company reported ($0.25) earnings per share for the quarter, missing analysts' consensus estimates of ($0.06) by $0.19. The medical research company earned $32.79 million during the quarter, compared to the consensus estimate of $32.86 million. Fluidigm had a negative trailing twelve-month return on equity of 28.73% and a negative net margin of 38.98%.
View Fluidigm's earnings history

How has Fluidigm's stock been impacted by COVID-19?

Fluidigm's stock was trading at $2.63 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, FLDM shares have increased by 181.7% and is now trading at $7.41.
View which stocks have been most impacted by COVID-19

What guidance has Fluidigm issued on next quarter's earnings?

Fluidigm issued an update on its second quarter 2021 earnings guidance on Thursday, May, 27th. The company provided earnings per share (EPS) guidance of - for the period. The company issued revenue guidance of $30 million-$32 million, compared to the consensus revenue estimate of $35.52 million.

What price target have analysts set for FLDM?

2 brokers have issued 1 year target prices for Fluidigm's shares. Their forecasts range from $7.00 to $16.00. On average, they anticipate Fluidigm's stock price to reach $11.50 in the next year. This suggests a possible upside of 55.2% from the stock's current price.
View analysts' price targets for Fluidigm
or view top-rated stocks among Wall Street analysts.

Who are Fluidigm's key executives?

Fluidigm's management team includes the following people:
  • Mr. Stephen Christopher Linthwaite, Pres, CEO & Director (Age 48, Pay $1.2M)
  • Mr. Vikram Jog, Chief Financial Officer (Age 65, Pay $667.25k)
  • Mr. Bradley Allen Kreger, Sr. VP of Global Operations (Age 46, Pay $560.62k)
  • Mr. Nicholas S. Khadder, Sr. VP, Gen. Counsel & Corp. Sec. (Age 47, Pay $481.58k)
  • Mr. Colin McCracken, Chief Commercial Officer (Age 48, Pay $734.78k)
  • Dr. Stephen R. Quake, Co-Founder & Chairman of Advisory Board (Age 51)
  • Mr. Andrew Quong, Chief Science Officer
  • Ms. Agnes Lee, VP of Investor Relations
  • Mark Spearman, Sr. Director of Corp. Communications
  • Ms. Angela Peters, Chief HR Officer

What is Chris Linthwaite's approval rating as Fluidigm's CEO?

30 employees have rated Fluidigm CEO Chris Linthwaite on Chris Linthwaite has an approval rating of 78% among Fluidigm's employees.

Who are some of Fluidigm's key competitors?

What other stocks do shareholders of Fluidigm own?

What is Fluidigm's stock symbol?

Fluidigm trades on the NASDAQ under the ticker symbol "FLDM."

Who are Fluidigm's major shareholders?

Fluidigm's stock is owned by many different retail and institutional investors. Top institutional shareholders include SkyOak Wealth LLC (0.24%). Company insiders that own Fluidigm stock include Levin Easterly Partners Llc, Nicolas Barthelemy, Samuel D Colella and Stephen Christopher Linthwaite.
View institutional ownership trends for Fluidigm

Which institutional investors are selling Fluidigm stock?

FLDM stock was sold by a variety of institutional investors in the last quarter, including SkyOak Wealth LLC.
View insider buying and selling activity for Fluidigm
or view top insider-selling stocks.

How do I buy shares of Fluidigm?

Shares of FLDM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Fluidigm's stock price today?

One share of FLDM stock can currently be purchased for approximately $7.41.

How much money does Fluidigm make?

Fluidigm has a market capitalization of $555.48 million and generates $138.14 million in revenue each year. The medical research company earns $-53,020,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis.

How many employees does Fluidigm have?

Fluidigm employs 627 workers across the globe.

What is Fluidigm's official website?

The official website for Fluidigm is

Where are Fluidigm's headquarters?

Fluidigm is headquartered at 2 Tower Place Ste 2000, South San Francisco CA, 94080.

How can I contact Fluidigm?

Fluidigm's mailing address is 2 Tower Place Ste 2000, South San Francisco CA, 94080. The medical research company can be reached via phone at 650-266-6000 or via email at [email protected]

This page was last updated on 7/30/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.